However, after randomly assigning hospitalized patients with COVID-19 and moderate or severe pneumonia to add-on treatment with tocilizumab (64 subjects) or usual care alone (67 subjects), Hermine et al. found that anti-IL-6R therapy lowered the need for mechanical ventilation and the death risk after 14 days, but did not change mortality on day 28 [73]. Here, IL6R is linked to COVID-19.